UroGen Pharma Ltd. – NASDAQ:URGN

Add to watchlist

$18.95

+8.19

+76.12%

Market open

Closed in about 4 hours

-36.44%

month

-36.44%

quarter

-25.28%

year

Market Cap	437.18M
Enterprise value	256.60M

P/E	-1.92
EV/Sales	6.74
EV/EBITDA	-2.53
Price/Sales	5.55
Price/Book	-3.34
PEG ratio	-0.12
EPS	-3.40

Revenue	84.30M
EBITDA	-66.29M
Income	-104.31M
Revenue Q/Q	9.24%
Revenue Y/Y	24.00%

Profit margin	-287.38%
Oper. margin	-206.73%
Gross margin	81.66%
EBIT margin	-206.73%
EBITDA margin	-78.64%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

UroGen Pharma Ltd. Stock Forecast

M Q Y

Last Year

$25

Potential upside: 31.92%

Analysts Price target
Financials & Ratios estimates

UroGen Pharma Ltd. (NASDAQ:URGN): Profit margin
Jun 2023	21.13M	-24.13M	-114.18%
Sep 2023	20.85M	-21.87M	-104.93%
Dec 2023	23.53M	-26.01M	-110.57%
Mar 2024	18.78M	-32.28M	-171.91%

UroGen Pharma Ltd. (NASDAQ:URGN): Debt to assets
Jun 2023	95361000	233.79M	245.17%
Sep 2023	193633000	235.62M	121.69%
Dec 2023	178311000	243.52M	136.57%
Mar 2024	200574000	240.70M	120.01%

UroGen Pharma Ltd. (NASDAQ:URGN): Cash Flow
Jun 2023	-20.27M	3.72M	143K
Sep 2023	-17.29M	401K	116.07M
Dec 2023	-13.05M	-10.98M	40K
Mar 2024	-31.73M	13.51M	54.65M

UroGen Pharma Ltd. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

UroGen Pharma Ltd. (NASDAQ:URGN): Employee count
Aug 2023	194
Sep 2023	193
Oct 2023	193
Nov 2023	193
Dec 2023	192
Jan 2024	192
Feb 2024	192
Mar 2024	198
Apr 2024	198
May 2024	198
Jun 2024	204
Jul 2024	204

UroGen Pharma Ltd.
Hedge Funds Holdings Q1 2022

63.63% -2.17%

of URGN is owned by hedge funds

80 +6

hedge funds hold URGN stock

14.21M -505.88K

shares is hold by hedge funds

URGN hedge funds holdings changes

UroGen Pharma Ltd.
Insider Trading

UroGen Pharma Ltd. (NASDAQ:URGN): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	0	3800
Jan 2024	0	8782
Feb 2024	0	8782
Mar 2024	0	12000
Jun 2024	0	5153

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	10 Jun 2024	SCHOENBERG MARK officer: Chief Me..	Ordinary Shares	10,000	N/A	N/A
Sale	10 Jun 2024	SCHOENBERG MARK officer: Chief Me..	Ordinary Shares	5,153	$13.08	$67,401
Option	10 Jun 2024	SCHOENBERG MARK officer: Chief Me..	Restricted Stock Units	10,000	N/A	N/A
Sale	18 Mar 2024	SCHOENBERG MARK officer: Chief Me..	Ordinary Shares	12,000	$14.05	$168,600
Sale	1 Feb 2024	SMITH JASON DREW officer: General ..	Ordinary Shares	3,328	$15.78	$52,516
Sale	1 Feb 2024	SMITH JASON DREW officer: General ..	Ordinary Shares	3,328	$15.78	$52,516
Sale	1 Feb 2024	SMITH JASON DREW officer: General ..	Ordinary Shares	1,248	$15.78	$19,693
Sale	1 Feb 2024	SMITH JASON DREW officer: General ..	Ordinary Shares	1,248	$15.78	$19,693
Sale	1 Feb 2024	SMITH JASON DREW officer: General ..	Ordinary Shares	417	$15.78	$6,580
Sale	1 Feb 2024	SMITH JASON DREW officer: General ..	Ordinary Shares	417	$15.78	$6,580

URGN insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application MATERIAL AND METHOD FOR TREATING CANCER Filling date: 9 Dec 2021 Issue date: 30 Jun 2022	9 Dec 2021	30 Jun 2022
Application	Application MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES Filling date: 31 Dec 2021 Issue date: 21 Apr 2022	31 Dec 2021	21 Apr 2022
Grant	Grant Utility: Connectable catheter Filling date: 25 Jun 2015 Issue date: 4 May 2021	25 Jun 2015	4 May 2021
Application	Application IMMUNOMODULATING TREATMENTS OF BODY CAVITIES Filling date: 31 Aug 2020 Issue date: 24 Dec 2020	31 Aug 2020	24 Dec 2020
Application	Application PHARMACEUTICAL COMPOSITIONS COMPRISING IMIQUIMOD FOR USE IN THE TREATMENT OF CARCINOMA IN SITU OF THE BLADDER Filling date: 4 Oct 2019 Issue date: 3 Sep 2020	4 Oct 2019	3 Sep 2020
Grant	Grant Utility: Immunomodulating treatments of body cavities Filling date: 11 Mar 2019 Issue date: 1 Sep 2020	11 Mar 2019	1 Sep 2020
Application	Application MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES Filling date: 22 Jul 2019 Issue date: 16 Apr 2020	22 Jul 2019	16 Apr 2020
Grant	Grant Utility: Material and method for treating internal cavities Filling date: 15 Oct 2013 Issue date: 12 Nov 2019	15 Oct 2013	12 Nov 2019

UroGen Pharma Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 13 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 14 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript

URGN earnings call transcripts

UroGen Pharma Ltd.
Executives

Insider	Age	Compensation
Ms. Elizabeth A. Barrett (1962) Pres, Chief Executive Officer & Director	63	$1,150,000
Dr. Mark P. Schoenberg (1958) Chief Medical Officer	67	$479,940
Mr. Jason Drew Smith (1972) Gen. Counsel & Chief Compliance Officer	53	$338,530
Ms. Molly Henderson CPA, MBA (1971) Chief Financial Officer	54	$279,340

UroGen Pharma Ltd.
Latest News

Friday, 6 December 2024
08:00	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 5 December 2024
15:30	Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®	businesswire.com
15:15	UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC	businesswire.com
Monday, 2 December 2024
18:45	Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade	zacks.com
08:00	UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs	businesswire.com
Tuesday, 26 November 2024
08:00	New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®	businesswire.com
Wednesday, 13 November 2024
08:02	UroGen Pharma: Choice Based On Near Term High Value PDUFA	seekingalpha.com
Wednesday, 6 November 2024
17:12	UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript	seekingalpha.com
10:15	Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
08:00	UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025	businesswire.com
Monday, 17 June 2024
22:51	UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants	businesswire.com
16:46	UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants	globenewswire.com
06:01	Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?	zacks.com
Thursday, 13 June 2024
10:54	Uber Advertising Announces Exclusive Partnership with T-Mobile Advertising Solutions	businesswire.com
10:49	AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100	businesswire.com
10:45	UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC	businesswire.com
Friday, 7 June 2024
08:00	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 6 June 2024
08:00	UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024	businesswire.com
Wednesday, 5 June 2024
08:00	UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference	businesswire.com
Monday, 3 June 2024
08:00	UroGen Pharma Appoints David Lin as New Chief Commercial Officer	businesswire.com
Wednesday, 22 May 2024
08:00	UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit	businesswire.com
Monday, 13 May 2024
18:30	UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Call Transcript	seekingalpha.com
08:00	UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights	businesswire.com
Tuesday, 7 May 2024
08:00	UroGen Pharma to Participate at Upcoming Investor Conferences	businesswire.com
Sunday, 5 May 2024
12:20	New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy	businesswire.com
Saturday, 4 May 2024
15:20	UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024	businesswire.com
11:50	New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial	businesswire.com
Friday, 3 May 2024
08:00	UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024	businesswire.com
Wednesday, 17 April 2024
12:02	UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers	businesswire.com
Monday, 15 April 2024
08:00	UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer	businesswire.com

Ideas & Opinions

Seeking Alpha 13 Jun 2025

UroGen Pharma: Lessons Learned And Future Outlook
Seeking Alpha 10 Jun 2025

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation
Seeking Alpha 21 May 2025

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either
Seeking Alpha 12 Apr 2025

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy
Seeking Alpha 31 Jan 2025

UroGen: Upcoming PDUFA, Some Concerns Remain
Seeking Alpha 9 Oct 2023

UroGen Pharma's Financial And Clinical Symbiosis
Seeking Alpha 8 Feb 2023

UroGen: Struggling With Revenue And With Cash Runway
Seeking Alpha 21 Nov 2022

UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns Remain

Frequently Asked Questions (FAQ)

What's the price of UroGen Pharma Ltd. stock today?

One share of UroGen Pharma Ltd. stock can currently be purchased for approximately $18.95.
When is UroGen Pharma Ltd.'s next earnings date?

Unfortunately, UroGen Pharma Ltd.'s (URGN) next earnings date is currently unknown.
Does UroGen Pharma Ltd. pay dividends?

No, UroGen Pharma Ltd. does not pay dividends.
How much money does UroGen Pharma Ltd. make?

UroGen Pharma Ltd. has a market capitalization of 437.18M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 28.52% to 82.71M US dollars.
What is UroGen Pharma Ltd.'s stock symbol?

UroGen Pharma Ltd. is traded on the NASDAQ under the ticker symbol "URGN".
What is UroGen Pharma Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of UroGen Pharma Ltd.?

Shares of UroGen Pharma Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are UroGen Pharma Ltd.'s key executives?
UroGen Pharma Ltd.'s management team includes the following people:
- Ms. Elizabeth A. Barrett Pres, Chief Executive Officer & Director(age: 63, pay: $1,150,000)
- Dr. Mark P. Schoenberg Chief Medical Officer(age: 67, pay: $479,940)
- Mr. Jason Drew Smith Gen. Counsel & Chief Compliance Officer(age: 53, pay: $338,530)
- Ms. Molly Henderson CPA, MBA Chief Financial Officer(age: 54, pay: $279,340)
How many employees does UroGen Pharma Ltd. have?

As Jul 2024, UroGen Pharma Ltd. employs 204 workers, which is 3% more then previous quarter.
When UroGen Pharma Ltd. went public?

UroGen Pharma Ltd. is publicly traded company for more then 8 years since IPO on 4 May 2017.
What is UroGen Pharma Ltd.'s official website?

The official website for UroGen Pharma Ltd. is urogen.com.
Where are UroGen Pharma Ltd.'s headquarters?

UroGen Pharma Ltd. is headquartered at 400 Alexander Park, Princeton, NJ.
How can i contact UroGen Pharma Ltd.?

UroGen Pharma Ltd.'s mailing address is 400 Alexander Park, Princeton, NJ and company can be reached via phone at +64 6 768 9780.
What is UroGen Pharma Ltd. stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for UroGen Pharma Ltd. in the last 12 months, the avarage price target is $25. The average price target represents a 31.92% change from the last price of $18.95.

UroGen Pharma Ltd.

urogen.com

Exchange:

NASDAQ

Full time employees:

217

Industry:

Biotechnology

Sector:

Healthcare

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

+64 6 768 9780

400 Alexander Park
Princeton, NJ 08540

CIK: 0001668243
ISIN: IL0011407140
CUSIP: M96088105